Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0128 (TAC-228) plus fulvestrant vs fulvestrant in ER-positive/HER2-negative advanced breast cancer after aromatase inhibitor
2015-003612-20Phase 2Terminated
- Sponsor
- Takeda
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sapanisertib in breast cancer (2 arms), sponsored by Takeda. Primary endpoint: Progression-free survival. Started Apr 2016; status: terminated.
02
Drugs
sapanisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-003612-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003612-20.